These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 29359607)

  • 21. A Phase 2a Study of Benralizumab for Patients with Eosinophilic Asthma in South Korea and Japan.
    Park HS; Kim MK; Imai N; Nakanishi T; Adachi M; Ohta K; Tohda Y;
    Int Arch Allergy Immunol; 2016; 169(3):135-45. PubMed ID: 27097165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
    FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
    Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matching-adjusted indirect comparison of benralizumab
    Bourdin A; Husereau D; Molinari N; Golam S; Siddiqui MK; Lindner L; Xu X
    Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30309978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Benralizumab: an updated treatment of eosinophilic asthma.
    Cushen B; Menzies-Gow A
    Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
    [No Abstract]   [Full Text] [Related]  

  • 25. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benralizumab for the treatment of asthma.
    Saco TV; Pepper AN; Lockey RF
    Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials.
    Liu T; Wang F; Wang G; Mao H
    Front Med; 2018 Jun; 12(3):340-349. PubMed ID: 29086236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
    Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
    Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
    Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
    Front Immunol; 2020; 11():593748. PubMed ID: 33488590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
    Sahota J; Robinson DS
    Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis.
    Edris A; De Feyter S; Maes T; Joos G; Lahousse L
    Respir Res; 2019 Aug; 20(1):179. PubMed ID: 31395084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?
    Menzella F; Latorre M; Ruggiero P; Bagnasco D; Heffler E
    Expert Opin Biol Ther; 2019 Jul; 19(7):601-606. PubMed ID: 31033373
    [No Abstract]   [Full Text] [Related]  

  • 37. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
    Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
    Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
    Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
    Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases.
    Sridhar S; Liu H; Pham TH; Damera G; Newbold P
    Respir Res; 2019 Jan; 20(1):14. PubMed ID: 30658649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
    Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
    Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.